Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to Buy at StockNews.com

StockNews.com downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) from a strong-buy rating to a buy rating in a report released on Tuesday.

REGN has been the subject of several other reports. UBS Group upped their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a buy rating in a research note on Wednesday, April 17th. Truist Financial reiterated a buy rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an overweight rating in a research report on Wednesday, March 13th. BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an outperform rating in a report on Monday, February 5th. Finally, Cantor Fitzgerald reiterated a neutral rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of Moderate Buy and a consensus target price of $977.77.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded down $1.82 on Tuesday, hitting $890.66. The stock had a trading volume of 627,942 shares, compared to its average volume of 491,369. The business's 50-day simple moving average is $945.77 and its two-hundred day simple moving average is $895.19. The stock has a market cap of $97.76 billion, a price-to-earnings ratio of 25.63, a price-to-earnings-growth ratio of 2.54 and a beta of 0.11. Regeneron Pharmaceuticals has a 52-week low of $684.80 and a 52-week high of $998.33. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter last year, the firm posted $10.96 earnings per share. The firm's revenue was up .6% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals will post 38.8 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the sale, the director now owns 18,382 shares in the company, valued at approximately $17,540,472.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Bonnie L. Bassler sold 854 shares of the firm's stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $979.25, for a total transaction of $836,279.50. Following the completion of the sale, the director now directly owns 1,382 shares of the company's stock, valued at approximately $1,353,323.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the transaction, the director now owns 18,382 shares of the company's stock, valued at approximately $17,540,472.04. The disclosure for this sale can be found here. Insiders have sold 10,195 shares of company stock valued at $9,759,898 over the last ninety days. 8.83% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. HB Wealth Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 49.3% in the 1st quarter. HB Wealth Management LLC now owns 1,671 shares of the biopharmaceutical company's stock valued at $1,608,000 after purchasing an additional 552 shares in the last quarter. Concord Wealth Partners lifted its holdings in Regeneron Pharmaceuticals by 10.2% during the first quarter. Concord Wealth Partners now owns 530 shares of the biopharmaceutical company's stock worth $510,000 after buying an additional 49 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its position in Regeneron Pharmaceuticals by 113.1% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 682 shares of the biopharmaceutical company's stock valued at $656,000 after acquiring an additional 362 shares in the last quarter. Caprock Group LLC increased its holdings in shares of Regeneron Pharmaceuticals by 8.5% in the 1st quarter. Caprock Group LLC now owns 865 shares of the biopharmaceutical company's stock valued at $833,000 after acquiring an additional 68 shares during the period. Finally, Perigon Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 32.2% in the 1st quarter. Perigon Wealth Management LLC now owns 8,080 shares of the biopharmaceutical company's stock valued at $7,777,000 after acquiring an additional 1,968 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.